Biogen (BIIB) Tops Q4 EPS by 25c, Offers Guidance

Biogen (NASDAQ: BIIB) reported Q4 EPS of $6.99, $0.25 better than the analyst estimate of $6.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.39 billion.

GUIDANCE:

Biogen sees FY2019 EPS of $28.00-$29.00, versus the consensus of $28.02. Biogen sees FY2019 revenue of $13.6-13.8 billion, versus the consensus of $13.63 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Wolfe Research Upgrades Biogen (BIIB) to Outperform
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
• Coherent, Inc. (COHR) Tops Q4 EPS by 12c, Offers Guidance